We investigated another main process that characterized the NAFLD physiopathology creating an in vitro model of hepatic fibrosis, administrating to LX2 cells the TGF-β protein, that is known to activate fibroblasts resulting in collagen release [58]. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatotic liver disease.